Choledocholithiasis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Albany, NY -- (SBWIRE) -- 01/22/2018 -- Choledocholithiasis is a condition wherein gall stones are found in the common bile duct instead of the gall bladder. Common bile duct is a small tube that carries bile from the gall bladder to the intestine. The condition is also known to occur in people whose gall bladder has been removed. Onset of symptoms is usually observed when gall stones start blocking the bile duct. Some of the symptoms include abdominal pain, fever, jaundice, loss of appetite, nausea, and vomiting. Complications may also include biliary cirrhosis, cholangitis, and pancreatitis. These stones cause blockage and infection. If not promptly diagnosed and treated, the disease can be life-threatening. The treatment for choledocholithiasis basically aims at relieving the blockage in the common bile duct. Different types of gall stones are cholesterol stones, pigment stones, and mixed stones. Cholesterol stones account for about 70% of gall stones. Diet is also known to play an important role in the prevention of formation of gall stones in the common bile duct.
Read Report Overview: https://www.transparencymarketresearch.com/choledocholithiasis-market.html
Stones in the common bile duct is a complicated disorder to diagnose. Initially, experts relate common symptoms of the disease such as nausea and vomiting with diagnostic tests. Generally, physicians confirm the presence of choledocholithiasis with abdominal ultrasound. In this test, the ultrasound shows shadows of stones in the gall bladder of the patient. Generally, diagnosis of choledocholithiasis is recommended if liver function blood tests show increase in levels of serum transaminases and bilirubin.
Major driving factors for the choledocholithiasis market are rise in elderly population, increase in prevalence of different gall bladder diseases, adoption of upgraded techniques and procedures for treating gall bladder diseases, and acceptance of different diagnostic treatment options. In 2013, biliary and gall-bladder-related diseases occurred in approximately 104 million people worldwide. Additionally, rise in health care expenditure, increase in government initiatives, rise in awareness about the disease are other factors likely to drive the choledocholithiasis market during the forecast period. On the other hand, complications during surgery and asymptomatic nature of gall stones may hinder the market in the near future.
Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33548
The global market for choledocholithiasis can be segmented based on diagnosis, blood test, treatment type, and geography. The diagnostic test segment includes abdominal CT scan, abdominal ultrasound, endoscopic retrograde cholangiography (ERCO), percutaneous trans-hepatic cholangiogram (PTCA), magnetic resonance cholangiopancreatography (MRCP), and endoscopic ultrasound. The blood test segment comprises tests for bilirubin, liver functioning, complete blood count (CBC), and pancreatic enzymes. Treatment for choledocholithiasis may involve medication, surgery, or sphincterotomy. Surgery is performed to remove the gall bladder and stones. Sphincterotomy involves a surgical cut into the muscle of the common bile duct removing stones.
Geographically, the global choledocholithiasis market has been segmented into five regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global choledocholithiasis market, followed by Europe. Rise in the number of gall bladder and bile duct-related disorders such as biliary cirrhosis, cholangitis, and pancreatitis; developed Infrastructure; wide acceptance of new in-vitro diagnostic techniques; and favorable reimbursement policies are some of the key factors boosting the North America market. However, rapidly increasing prevalence of choledocholithiasis and related diseases in Asia Pacific is anticipated to drive the market in the region in the next few years. Major countries of the region such as India, China, and Japan have a large population suffering from bile duct and gall bladder-related disorders. Additionally, the rise in awareness about health care, surge in the demand for early diagnosis and precise treatment of the disorder, increase in government initiatives, and rise in per capita income are other factors driving the market.
Pre Book Choledocholithiasis Market Research Report: https://www.transparencymarketresearch.com
Some of the key players operating in the global choledocholithiasis market are Astra Zeneca, Novartis, GSK, Pfizer, Abbott Laboratories, GE Healthcare, Celgene Corporation, and Eli Lilly and Company.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.